Suchergebnisse - "Montesinos, Pau"

PubPharm (9)

1

Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

enthalten in: Cancer | 2021

von Kantarjian, H. | Begna, K. | Altman, J. | +25

2

A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia

enthalten in: Cancer | 2021

von Vives, S. | Martínez-Cuadrón, D. | Bergua Burgues, J. | +31

3

A phase 3 trial of azacitidine versus a semi‐intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia

enthalten in: Cancer | 2021

von Vives, S. | Martínez‐Cuadrón, D. | Bergua Burgues, J. | +30

4

Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

enthalten in: Cancer | 2021

von Kantarjian, H. | Begna, K. | Altman, J. | +25

5

Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group

enthalten in: Cancer | 2019

von Ribera, J. | García, O. | Moreno, M. | +25

6

Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols

enthalten in: Cancer | 2015

von Ribera, J. | Morgades, M. | Zamora, L. | +29

7

Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols

enthalten in: Cancer | 2014

von Motlló, C. | Ribera, J. | Morgades, M. | +18

8

Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status : final results of a phase 2 study (Burkimab)

enthalten in: Cancer | 2013

von Ribera, J. | García, O. | Grande, C. | +17

9

A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia

enthalten in: Cancer | 2012

von Valcárcel, D. | Montesinos, P. | Sánchez-Ortega, I. | +13

1
[1]